Larimar Therapeutics Inc. (LRMR) Submits First Module for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia

Larimar Therapeutics, Inc. (Nasdaq: LRMR), a clinical‑stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, has submitted the first module of a rolling Biologics License Application (BLA) for its lead compound, nomlabofusp, targeting Friedreich’s ataxia. The filing is part of a strategy to obtain accelerated approval from the U.S. Food and Drug Administration (FDA) based on positive open‑label data from the ongoing long‑term study.

Regulatory Filing

  • Submission date: 29 June 2026
  • Document: Rolling BLA, first module
  • Purpose: Accelerated approval pathway for a rare disease indication

The submission follows a series of positive results from the open‑label trial, which have prompted the company to pursue accelerated approval.

Investor Communications

  • Investor event: Larimar scheduled a webcast on 29 June 2026 at 7:45 am ET to discuss regulatory updates and new data.
  • Event details: The webcast will be available live and archived on the company’s website under “Events & Presentations.”

Stock Market Impact

  • Pre‑market movement: In early trading on 29 June, LRMR experienced a significant price swing, reflecting investor reaction to the accelerated approval filing.
  • Current price (25 June 2026): $3.66 per share, within a 52‑week range of $2.72–$6.42.
  • Market cap: $380 million.
  • Price‑earnings ratio: –1.74, indicating negative earnings typical of a clinical‑stage company.

Context

Larimar Therapeutics focuses on developing treatments for rare complex diseases, notably through protein replacement therapy. The company’s portfolio is concentrated in the United States, with a primary customer base in Pennsylvania. The nomlabofusp program represents the company’s most advanced asset, aiming to provide a disease‑modifying therapy for Friedreich’s ataxia, a debilitating neuro‑degenerative condition.

The accelerated approval filing underscores Larimar’s intent to bring its therapy to market faster, contingent upon meeting the FDA’s post‑approval study requirements. The upcoming investor event will provide further clarification on regulatory strategy, clinical data, and future milestones.